Drugs / MIYAIRI 588
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05759741 | Jan 2023 → Jul 2024 | rectal cancer | Huashan Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05724511 | Feb → Jun 2023 | cardiovascular disorder, depressive disorder | China Medical University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIYAIRI 588 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05724511 ↗ |
| Known as | C. butyricum MIYAIRI 588 | “The investigators provide probiotics (C. butyricum MIYAIRI 588) to intervention group and provide nothing to the control group.” NCT05724511 ↗ |
| Modality | Other / unclassified | “The investigators provide probiotics (C. butyricum MIYAIRI 588) to intervention group” NCT05724511 ↗ |
| Route | Oral | “each subjects take 1g/package with meal” NCT05724511 ↗ |